NATERA INC. DL-,0001

Natera shares rose to a record high of 343.94 USD, lifting market capitalization to about 49.4 billion USD. The stock posted a one‑year total return of 98.5%, driven by strategic growth initiatives, record test volumes, improved margins and regulatory wins. In the second quarter Natera reported revenue of roughly 753 million USD and raised its full‑year guidance, while analysts at Rothschild Redburn initiated coverage with a "Buy" and a 385 USD price target. InvestingPro, however, points to a possible overvaluation relative to fair value. » More on de.investing.com

Stanley Druckenmiller’s Duquesne reported 44 new buys and 23 complete sells in Q2; reported portfolio value rose from $3.38 billion to $5.21 billion. Natera remains the largest single holding at about 16.6% or roughly $865 million and was increased by about $252 million. Amazon and Alphabet positions were significantly expanded or reintroduced, while names including Broadcom, Intel and Micron were sold; TSMC and AMD were increased. Several smaller purchases focus on crypto and data-center plays, complementing the bet on expanding computing power. The 13F filing captures only US long equities and call options, so much of the macro trading is not reflected. » More on deraktionaer.de

Natera is providing its personalized Signatera ctDNA test for an Angiex phase I trial of the investigational antibody–drug conjugate AGX101. The study is evaluating patients with unresectable, locally advanced or metastatic solid tumors and uses longitudinal ctDNA measurements to monitor treatment response alongside imaging. Natera and Angiex expect that ctDNA analyses can offer additional insights into early biological response rates and the effect of AGX101’s dual-targeting mechanism. » More on de.investing.com

Billionaire Stanley Druckenmiller's Duquesne Family Office has raised healthcare exposure from ~22% to over 36% of its portfolio, concentrating in high-conviction biotech and diagnostics. The fund's largest position is Natera, now about 17% of assets after a Q2 purchase, citing strong revenue growth, improving margins and rising testing volumes. Duquesne also added Insmed and holds Rhythm Pharmaceuticals while rotating out legacy pharmas and tactically shifting into cyclical sectors as macro conditions change. » More on finance.yahoo.com

Stanley Druckenmiller's latest 13F shows he increased positions in Amazon and Alphabet but placed Natera as his single biggest holding. Natera is a molecular diagnostics company focused on cell-free DNA testing with franchises in women's health, oncology and transplant surveillance, led by its Signatera MRD test. The company posted Q2 2026 revenue of $752.8 million, processed about 1,043,900 tests, raised full-year revenue guidance to $2.85–2.91 billion and expects positive cash flow for the year. Key risks include high SG&A and R&D spending, regulatory and reimbursement uncertainty, competition and stretched valuation. » More on finance.yahoo.com